Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Overview
Bio-Techne Corporation (NASDAQ: TECH) is a globally recognized life sciences company offering innovative bioactive reagents, consumables, and instruments. Its extensive portfolio supports a broad spectrum of applications in clinical diagnostics, drug discovery, and biological research. Using advanced immunoassays, spatial biology tools, and protein analysis reagents, Bio-Techne equips scientists with the essential resources to investigate complex biological processes and disease mechanisms.
Core Business Areas
Bio-Techne organizes its operations into two primary segments:
- Protein Sciences: This segment supplies specialized reagents such as antibodies, cytokines, and growth factors, along with analytical instruments, that serve as critical tools for protein analysis and cell biology. These products are employed in both basic and advanced research settings, reflecting a strong commitment to scientific precision and reproducibility.
- Diagnostics and Spatial Biology: Focused on clinical diagnostic solutions, this segment offers molecular tests, diagnostic reagents, and spatial biology products. These tools facilitate reliable clinical assays, supporting translational research and precision medicine through enhanced imaging and biomarker analysis.
Global Reach and Market Position
Based in Minnesota, Bio-Techne has established a significant market presence globally. Its products are widely used in North America, Europe, the Middle East, Africa, the UK, and Asia-Pacific. This international footprint, combined with a deep and diverse product catalog, positions the company as a key contributor to high-quality scientific research and diagnostic testing worldwide.
Innovation and Strategic Collaborations
Innovation is at the core of Bio-Techne’s operations. The company invests heavily in research and development to integrate emerging technologies, such as AI-assisted protein design and automated spatial biology platforms, into its product lines. Strategic collaborations with academic institutions, industry partners, and regional distributors further enhance its capabilities and propel breakthrough innovations. These partnerships not only accelerate product development but also ensure that the tools provided are seamlessly integrated into existing research and clinical workflows.
Product Portfolio and Revenue Streams
Bio-Techne offers an extensive inventory of bioactive reagents and research tools. Its products cater to a wide array of scientific needs ranging from basic research to clinical diagnostics. By providing both Research Use Only (RUO) and Good Manufacturing Practice (GMP) grade products, the company meets the rigorous demands of biotechnology, pharmaceutical, and academic sectors. Its revenue is generated through direct sales, licensing agreements, and strategic distribution deals, all of which underscore the company’s role as a pivotal enabler of scientific exploration.
Competitive Landscape
In a crowded marketplace, Bio-Techne stands out by leveraging its robust product portfolio, cutting-edge technological integration, and a proven track record of intellectual property innovation. While competitors offer similar life sciences tools, Bio-Techne differentiates itself with high-quality, reliable products and ongoing legal protections that reinforce its investment in research and development.
Customer Focus and Operational Excellence
The company prioritizes customer success by delivering reproducible and high-performance research tools that enhance scientific discovery. It regularly engages with the scientific community through educational workshops, technical discussions, and industry events, ensuring its customers remain at the forefront of innovation. This commitment to operational excellence has solidified Bio-Techne’s reputation as a trusted partner in both research and clinical diagnostic communities.
Conclusion
Overall, Bio-Techne Corporation is a cornerstone in the life sciences industry. Through its dual focus on Protein Sciences and Diagnostics & Spatial Biology, the company provides essential tools and innovative solutions that empower researchers and clinicians alike. Its global reach, strategic collaborations, and continuous push for technological advancement highlight its pivotal role in advancing biomedical research and clinical diagnostics.
Bio-Techne (NASDAQ: TECH) will showcase its portfolio at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting from November 6-10, 2024, in Houston, Texas. The company's spatial biology brands, Advanced Cell Diagnostics (ACD) and Lunaphore, will present their innovations at booths #613 and #701 respectively.
ACD will showcase spatial multiomics products featuring RNAscope™ technology, while Lunaphore will demonstrate its automated COMET™ suite and HORIZON™ image analysis software. The company will present multiple posters highlighting research applications, including multiomic mapping of the brain, immune cell profiling, and biomarker detection studies. Collaborative research presentations with prominent institutions will also be featured.
Bio-Techne announced significant clinical data from its Lunaphore COMET spatial biology platform. The platform integrates with clinical research workflows and uses IHC-validated antibodies for rapid panel development. Research conducted with the National Tumor Institute and Nucleai revealed tumor microenvironment features that could predict therapy response in melanoma patients. The study combined multiplex immunofluorescence with AI-powered biomarker analysis, marking the first application of this technology in a clinical trial. Additional research with Johns Hopkins University demonstrated the platform's novel amplification technique for comprehensive tumor profiling.
Bio-Techne (NASDAQ: TECH) has declared a quarterly dividend of $0.08 per share for the quarter ended September 30, 2024. The dividend will be paid on November 22, 2024, to shareholders of record as of November 11, 2024. The company, which provides innovative tools and bioactive reagents for research and clinical diagnostics, reported net sales of approximately $1.2 billion in fiscal 2024 and employs around 3,100 people globally.
Bio-Techne (NASDAQ: TECH) reported Q1 FY2025 results with organic revenue growth of 4% (5% reported) to $289.5 million. GAAP EPS decreased to $0.21 from $0.31 year-over-year, while adjusted EPS slightly increased to $0.42 from $0.41. The Diagnostics & Spatial Biology segment showed strong performance with 14% organic growth. The Protein Sciences segment remained flat at $204.5 million with 1% organic growth. GAAP operating margin declined to 13.8% from 20.2%, while adjusted operating margin decreased to 29.0% from 31.4% due to product mix and compensation accruals.
ScaleReady announced that Luminary Therapeutics has been awarded a $300,000 G-Rex® Grant in collaboration with Wilson Wolf Manufacturing and Bio-Techne (NASDAQ: TECH). The grant will support development of novel CAR γδ T cell therapies for autoimmune conditions. Luminary's approach combines Vδ1 and Vδ2 subsets with immune cloaking mechanism and utilizes Bio-Techne's TcBuster™ technology. The company claims their manufacturing process can produce 180-200 patient doses per run at less than $10,000 per drug product. The grant is part of ScaleReady's $20M initiative to advance cell and gene therapy development.
Bio-Techne (NASDAQ: TECH) has announced a conference call and webcast scheduled for October 30, 2024, at 8:00 a.m. CDT to discuss its first quarter fiscal 2025 financial results. Interested parties can access the call via phone or webcast. The dial-in numbers are 1-877-407-9208 for domestic callers and 1-201-493-6784 for international callers, with the Conference ID 13749405. A webcast link is also provided.
For those unable to join the live call, a recorded rebroadcast will be available from 11:00 a.m. CDT on October 30, 2024, until 11:00 p.m. CST on November 30, 2024. The replay can be accessed by dialing 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and using the same Conference ID.
ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH), and CellReady, has awarded a $300,000 G-Rex® Grant to LIfT BioSciences. This grant will support the clinical manufacturing of LIfT's Neutrophil only Leukocyte Infusion Therapy (N-LIfT) platform, a promising allogeneic innate cell therapy.
The N-LIfT platform produces Immunomodulatory Alpha Neutrophils (IMANs), enhanced neutrophils designed to overcome treatment resistance in solid tumors. IMANs can identify and kill solid tumors irrespective of antigen, both directly and indirectly by recruiting the patient's own cancer-killing immune cells.
LIfT will collaborate with ScaleReady to establish a fully closed and semi-automated G-Rex manufacturing process suitable for late-stage clinical trials and beyond. The G-Rex Grant Program is a $20M initiative to advance cell and gene-modified cell therapy development and manufacturing.
ScaleReady has awarded a G-Rex Grant of $200,000 to Dr. Eric Tran of the Earle A. Chiles Research Institute, a division of Providence Cancer Institute. The grant will support process development and IND enabling studies for a novel KRAS-targeted TCR-T cell therapy.
Dr. Tran plans to optimize the manufacturing process by reducing duration and implementing fully-closed system G-Rex bioreactors. The project will utilize Bio-Techne's new GMP cytokines, designed for one-touch G-Rex close process manufacturing.
The G-Rex Grant Program is a $20M initiative by ScaleReady to advance cell and gene-modified cell therapy development and manufacturing. Recipients gain access to support from G-Rex Grant Partners, offering expertise in cGMP manufacturing, quality and regulatory affairs, and CGT business operations.
ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH), and CellReady, has awarded a $300,000 G-Rex® Grant to Dr. Christopher A. Klebanoff, a renowned cancer immunologist at Memorial Sloan Kettering Cancer Center (MSK). The grant will support the development of a novel CD8α/β-armored TCR-T cell therapy targeting an HLA-A*11:01-restricted RAS (G12D) public neoantigen for a Phase 1 clinical trial.
The grant will provide enabling reagents for process development, IND-enabling studies, and clinical manufacturing. Dr. Klebanoff's team plans to incorporate Wilson Wolf's fully closed-system G-Rex bioreactors and the GatheRex for cell processing. The project aims to develop a robust manufacturing framework for generating infusion products for cancer patients, potentially benefiting those with treatment options.
As part of the grant, MSK will receive early access to Bio-Techne's new line of closed system GMP reagents, including the G-Rex ProPak™ CAR-TCR Cytokine Kits, designed for use with G-Rex bioreactors.
Bio-Techne (NASDAQ: TECH) announced a partnership between its spatial biology brand, Lunaphore, and Discovery Life Sciences (Discovery). The collaboration aims to integrate Lunaphore's COMET™ platform into Discovery's global suite of biospecimen products and specialty lab services for clinical research.
The partnership combines COMET technology, a fully-automated, high-throughput, hyperplex platform for tissue profiling, with Discovery's scientific expertise. This collaboration is expected to advance research in immuno-oncology, immunology, neuroscience, and infectious diseases across all development stages.
Discovery's new Lunaphore COMET Hyperplex Immunofluorescence Services will support the development of next-generation assays for clinical trials and provide multidimensional spatial biology insights. The partnership aims to accelerate biomarker discovery, patient stratification, and translational medicine.
FAQ
What is the current stock price of Bio-Techne (TECH)?
What is the market cap of Bio-Techne (TECH)?
What are the primary business segments of Bio-Techne Corporation?
How does Bio-Techne support scientific research?
What distinguishes Bio-Techne in a competitive market?
Who are the main customers of Bio-Techne Corporation?
How does Bio-Techne ensure product quality and reliability?
What role do strategic partnerships play for the company?
Can you describe the global presence of Bio-Techne?
